Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias
Most Cited Paper
in Acute Myeloid Leukemia Research
18 Months Post-Publication
Class of 2026
“Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
JNJ-75276617 · bleximenib · Menin inhibitor · KMT2A-rearranged leukemia · NPM1-mutated AML · protein-protein interaction inhibitor · MEIS1 · FLT3 · Acute myeloid leukemia (AML) · acute lymphoblastic leukemia · gilteritinib · Venetoclax · Azacitidine · MEN1M327I mutation · MEN1T349M mutation · revumenib resistance · Patient-derived xenograft models · chromatin binding inhibition · cocrystal structure · drug synergy
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459